Status In progress
Process STA pre-2018
ID number 1115

Provisional Schedule

Committee meeting: 1 31 July 2018

Project Team

Project lead Stephanie Callaghan

Email enquiries

Consultees

Companies sponsors Kite, a Gilead company (axicabtagene ciloleucel)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Leukaemia CARE
  Lymphoma Association
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord healthcare (cytarabine, doxorubicin, etoposide) (confidentiality agreement not signed, not participating)
  Actavis (etoposide) (confidentiality agreement not signed, not participating)
  Aspen (melphalan)
  Baxter healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb (etoposide) (confidentiality agreement not signed, not participating)
  Celltrion Healthcare (Truxima) (confidentiality agreement not signed, not participating)
  Eisai (carmustine) (confidentiality agreement not signed, not participating)
  Hospiria UK (cytarabine, vincristine) (confidentiality agreement not signed, not participating)
  Janssen-Cilag (doxorubicin)
  Medac GmbH (doxorubicin, etoposide) (confidentiality agreement not signed, not participating)
  Napp pharmaceuticals (rituximab, cytarabine) (confidentiality agreement not signed, not participating)
  Pfizer (cytarabine, doxorubicin) (confidentiality agreement not signed, not participating)
  Roche (rituximab)
  Sandoz (rituximab, cyclophosphamide) (confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (doxorubicin) (confidentiality agreement not signed, not participating)
  Servier Laboratories Ltd (pixantrone)
  Teva (doxorubicin, vincristine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
30 May 2018 NICE will be conducting a technical engagement step; providing questions to targeted stakeholders to assist in identifying the most plausible assumptions in the clinical and cost-effectiveness analysis for this technology. Stakeholders that are invited to take part will be provided with technical engagement documentation, including questions and guidance for response. Comments from the technical engagement will be collated and summarised as part of the committee pre-meeting briefing document. This will be made available to all stakeholders with a signed confidentiality agreement as part of the committee papers accompanying the post committee documentation (ACD or FAD) following the meeting on 31 July 2018. The committee papers will be posted on the NICE website as normal (5 working days following release to stakeholders).
16 May 2018 The first appraisal committee discussion for this topic was planned for Wednesday 30 May 2018. Following recent discussions involving the company (Kite/Gilead), NHS England and NICE on the elements important to this appraisal (including commercial, technical and service delivery aspects), NICE has taken the decision to re-schedule this first meeting to Tuesday 31 July 2018. NICE, NHS England and the company are committed to fully collaborate to ensure that the committee has all of the appropriate evidence to enable it to make the most informed and robust decision for this technology for patients with diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma.
08 December 2017 In progress, In progress
07 December 2017 Invitation to participate
19 September 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance